St.Petersburg, Florida Oct. 20-23, 2019
15th International Bioactive Lipids Conference
Puerto Vallarta, Mexico – October 22-25, 2017
Editor-in-Chief, New England Journal of Medicine
Distinguished Parker B. Francis Professor of Medicine
Harvard Medical School
Dr. Jeffrey Drazenwas selected as the first recipient of Eicosanoid Research Foundation’s Exceptional Contributions to Human Physiology and Translational Medicine Award
Dr. Drazen majored in applied physics at Tufts University and graduated from Harvard Medical School in 1972. He currently holds the positions of senior physician at the Brigham and Women’s Hospital, Distinguished Parker B. Francis Professor of Medicine at Harvard Medical School, professor of physiology at the Harvard School of Public Health and adjunct professor of medicine at the Boston University School of Medicine. He is the recipient of honorary degrees from the University of Ferrara, the University of Athens and the University of Modena.
Dr. Drazen is an elected member of the American Society for Clinical Investigation, the Association of American Physicians, the Interurban Clinical Club and the National Academy of Medicine. He serves on the National Academy of Medicine’s Forum on Drug Discovery, Development, and Translation. An active researcher in the field of pulmonary medicine, Dr. Drazen defined the role of novel endogenous chemical agents in asthma, leading to four licensed pharmaceuticals for asthma, now used by tens of millions of people worldwide. He has published over 500 papers, editorials and review articles and has edited ten books, including Goldman-Cecil Medicine and Asthma and COPD.
In 2000, Dr. Drazen became editor-in-chief of the New England Journal of Medicine. Since then, the Journal has published major papers advancing the science of medicine, including the first descriptions of SARS, timely coverage of the Ebola and Zika virus epidemics, and advances in the treatment of cancer, heart disease and lung disease. It has been at the forefront of worldwide efforts to register all clinical trials and to share clinical trial data. The Journal now has over a million and a half readers every week and the highest impact factor of any journal publishing original research.